Ifosfamide by bolus as treatment for advanced non-small cell lung cancer.
AffiliationCancer Research Campaign, Department Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, England.
MetadataShow full item record
AbstractIfosfamide at 5 g/m2 was given as a bolus to 48 patients with advanced progressing non-small cell lung cancer. Mesna (5 g/m2) was also given with the ifosfamide, both over 30 min. Further mesna was then given p.o. (3 g/m2) at 4, 8, and 12 h. If oral mesna was not acceptable then one or, if necessary, two 4-h to 6-h infusions (3 g/m2) were administered. A maximum of six courses at 3-weekly intervals was prescribed. A total of 174 courses was administered, and oral mesna was given during 64 courses: discharge was considered possible within 8-10 h after 55% of courses. Haematological toxicity was mild and no renal dysfunction was noted. Two patients became drowsy shortly after ifosfamide, but recovered 24-36 h later. The objective response rate was 29%, with one complete responder. A further 31% of patients (symptomatic responders) with stable disease symptomatically improved after the chemotherapy, by 20 or more points on the Karnofsky scale. The median survival was 5 months for the whole group, and 8 months each for the objective and symptomatic responder groups. Most patients' Karnofsky and respiratory scores improved with the chemotherapy. Ifosfamide with mesna can be given by short infusions, and the mesna given p.o. prevents any urothelial toxicity. Further exploration of short-infusion ifosfamide and mesna therapy would reduce hospitalization and allow for day-case regimens.
CitationIfosfamide by bolus as treatment for advanced non-small cell lung cancer. 1986, 18 Suppl 2:S30-3 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer. From the Manchester Lung Tumour Group.
- Authors: Thatcher N, Smith DB, Lind MJ, Anderson H, Barclay J, Chopra MP, Fitzgerald MD
- Issue date: 1988 Jan 1
- Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
- Authors: Manegold C, Drings P, Pawinski A, Lentz MA, van Glabbeke M, van Zandwijk N, Bachmann P, Schnaars Y, Skacel Z, Zatloukal P, Dolensky J, Jackevicius A, Petruzelka L, Giaccone G
- Issue date: 1996 Aug
- Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
- Authors: Nobile MT, Rosso R, Brema F, Cinquegrana A, Santi L
- Issue date: 1984 Oct 31
- The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
- Authors: Cantwell BM, Bozzino JM, Corris P, Harris AL
- Issue date: 1988 Feb
- Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer.
- Authors: Manegold C, Bischoff H, Fischer JR, Löchner S, Peukert M, Schmähl A, Drings P
- Issue date: 1992 Nov